SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-B
FOR REGISTRATION OF SECURITIES OF
CERTAIN SUCCESSOR ISSUERS
FILED PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
CVS CORPORATION
(Successor to Melville Corporation)
(Exact name of registrant as specified in its charter)
Delaware Applied For
(State of (I.R.S. Employer
incorporation or Identification Number)
organization)
One CVS Drive, Woonsocket, Rhode Island 02895
(Address of principal executive offices) (Zip Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class Name of each exchange on which
to be so Registered each class is to be registered
Common Stock of New York Stock Exchange, Inc.
CVS Corporation,
par value $.01 per share
Securities registered pursuant to Section 12(g) of the Act:
None
Item 1. General Information.
(a) CVS Corporation ("CVS" or the "Registrant") was organized as a
corporation on August 22, 1996 under the laws of the State of Delaware.
(b) The Registrant's fiscal year ends on December 31 of each year.
Item 2. Transaction of Succession.
(a) Melville Corporation, a New York corporation ("Melville"), which
will be the predecessor of the Registrant at the time of the succession, has
securities registered pursuant to Section 12(b) of the Securities Exchange Act
of 1934, as amended ("the Exchange Act").
(b) This Registration Statement is filed in connection with the
proposal (the "Proposal") to reincorporate Melville in Delaware and, in
connection therewith, to effect certain charter and bylaw amendments, all as
described under "III. Proposal: To Change the State of Incorporation From New
York to Delaware and to Effect Certain Charter Amendments" in the Proxy
Statement dated October 7, 1996 (the "Proxy Statement") mailed to Melville
shareholders in connection with the Proposal, which is attached hereto as
Exhibit 2.1 and incorporated by reference herein and made a part hereof. The
Proposal entails (i) the reincorporation to Delaware from New York through the
merger structure described below resulting in (x) Melville shareholders owning
shares of a new Delaware holding company named "CVS Corporation" and (y)
Melville thereby becoming a wholly owned subsidiary of CVS, and (ii) in
connection therewith, effecting the amendments to the holding company's
certificate of incorporation and bylaws described below, all as more fully
described in the Proxy Statement.
The proposed reincorporation from New York to Delaware will be
effected by a triangular merger structure pursuant to which Melville will
become a wholly owned subsidiary of CVS. Under the proposed merger structure,
CVS New York, Inc. ("Merger Subsidiary"), a wholly-owned New York subsidiary
of CVS organized for such purpose shall be merged with and into Melville (the
"Merger"). Melville will be the surviving corporation (the "Surviving
Corporation") in the Merger and will be renamed "CVS New York, Inc." Pursuant
to the Merger, at the Effective Time (as defined below) and as further
described below, each shareholder of Melville will receive an equal number of
shares of CVS in exchange for each share of capital stock of Melville held by
such shareholder immediately prior to the Effective Time.
The Merger will be effected pursuant to an Agreement and Plan of
Merger (the "Merger Agreement"), dated as of August 30,1996, by and among
Melville, CVS and Merger Subsidiary (which is attached as Appendix A to the
Proxy Statement and is incorporated by reference herein). The Merger will
become effective at such time, after the Merger Agreement has been duly
authorized and adopted by the requisite approval of shareholders of Melville,
as the certificate of merger is duly filed with the Secretary of State of the
State of New York or at such later time as is specified in the certificate of
merger (the "Effective Time"). From and after the Effective Time, the
Surviving Corporation will possess all the rights, privileges, powers and
franchises and be subject to all of the restrictions, disabilities and duties
of Melville and Merger Subsidiary, all as provided under New York law.
Pursuant to the Merger, subject to the exercise and perfection
of dissenting shareholders' appraisal rights as described in the Proxy
Statement, at the Effective Time: (i) each share of common stock, par value
$1.00 per share ("Melville Common Stock"), of Melville issued and outstanding
(or share credit with respect thereto), or held in the treasury of Melville,
shall be converted (without the surrender of stock certificates or any other
action) into one fully paid and nonassessable share of common stock, par value
$.01 per share (the "CVS Common Stock"), of CVS, issued and outstanding (or
share credit with respect thereto) or held in the treasury of CVS, as the case
may be (with the same rights, powers and privileges as the shares or share
credits so converted); (ii) each share of Series One ESOP Convertible
Preference Stock, par value $1.00 per share ("Melville ESOP Preference
Stock"), of Melville issued and outstanding shall be converted (without the
surrender of stock certificates or any other action) into one fully paid and
nonassessable share of Series One ESOP Convertible Preference Stock, par value
$1.00 per share (the "CVS ESOP Preference Stock"), of CVS issued and
outstanding (with the same rights, powers and privileges as the shares so
converted); (iii) each share of common stock of Merger Subsidiary issued and
outstanding immediately prior to the Effective Time shall be converted into
and become one share of common stock of the Surviving Corporation with the
same rights, powers and privileges as the shares so converted and shall
constitute the only outstanding shares of capital stock of the Surviving
Corporation; and (iv) each option (a "Melville Option") to purchase or acquire
shares of Melville Common Stock which has been granted pursuant to any
employee or director stock option or compensation plan or arrangement of
Melville shall be, without any action on the part of the optionee, converted
into an option to purchase or acquire the same number of shares of CVS Common
Stock on the same terms and with the same exercise price as were applicable
with respect to such Melville Option immediately prior to the Effective Time.
Following the Effective Time, all Melville employee and director stock-based
benefits or compensation plans and arrangements will be transferred to CVS,
and all other Melville benefits and compensation plans and arrangements will
be maintained by the Surviving Corporation or transferred to CVS.
At the Effective Time, the amended and restated certificate of
incorporation (the "CVS Charter") and bylaws ("CVS Bylaws") of CVS will be in
effect and will govern the rights of stockholders in the event the Proposal
is approved. The CVS Charter is substantially similar to Melville's
certificate of incorporation. Except for provisions relating to change in
name, corporate purpose, indemnification and limitation of liability of
directors and officers, the ability to call special meetings of stockholders,
and amending the bylaws, the differences between the two are primarily the
result of the differences between the New York Business Corporation Law and
the Delaware General Corporation Law ("Delaware GCL"). The bylaws of CVS and
Melville are substantially similar except that the bylaws of CVS reflect the
Delaware GCL and the provisions of the CVS Charter. A description of the
material differences between the CVS Charter and CVS Bylaws and Melville
certificate of incorporation and Melville bylaws is set forth in the Proxy
Statement under "Material Changes in the CVS Charter and Bylaws From the
Melville Charter and Bylaws." The text of the CVS Charter and CVS Bylaws are
attached as Appendices B and C, respectively, to the Proxy Statement and are
incorporated by reference herein and made a part hereof.
From and after the Effective Time, until successors are duly
elected or appointed and qualified in accordance with applicable law, (i) the
directors of Melville at the Effective Time shall be the directors of CVS, and
(ii) the officers of Melville at the Effective Time shall be the officers of
CVS.
The Proposal will be submitted to the shareholders of Melville
at its Special Meeting of Shareholders which is scheduled for November 19,
1996, and the Merger is expected to become effective as soon as practicable
thereafter. For a complete description of the Proposal and other relevant
information, reference is made to the Proxy Statement. The foregoing
discussion under Item 2 is qualified in its entirety by reference to the Proxy
Statement.
Item 3. Securities to be Registered.
The securities being registered hereunder are the Common Stock,
par value $.01 per share, of CVS.
Immediately prior to the Effective Time, the designation and
number of authorized shares of CVS under the CVS Charter will be 350,120,619
shares of capital stock of which (i) 300,000,000 shares are CVS Common Stock,
(ii) 120,619 shares are Cumulative Preferred Stock, $.01 par value per share
("CVS Cumulative Preferred Stock"), and (iii) 50,000,000 are Preference Stock,
$1 par value per share ("CVS Preference Stock") (CVS Cumulative Preferred
Stock and CVS Preference Stock being referred to herein collectively as
"Preferred Stock"). At the Effective Time, (1) CVS will have outstanding the
same number of shares of CVS Common Stock and shares of CVS ESOP Preference
Stock as there were outstanding shares of Melville Common Stock and shares of
Melville ESOP Preference Stock immediately prior to such time, and (2) no
shares of CVS Cumulative Preferred Stock will be issued or outstanding. In
addition, at the Effective Time, CVS will hold in its treasury the same number
of shares of CVS Common Stock as there were shares of Melville Common Stock
held in the treasury of Melville.
Item 4. Description of Registrant's Securities to be Registered.
At the Effective Time, the authorized capital stock of the
Registrant will consist of 300,000,000 shares of CVS Common Stock, 120,619
shares of CVS Cumulative Preferred Stock and 50,000,000 shares of CVS
Preference Stock.
The following is a summary of certain provisions of the CVS Charter
and CVS Bylaws which are attached as Appendix B and Appendix C to the Proxy
Statement, and incorporated herein by reference, and the following summary is
qualified in its entirety by reference to such documents.
CVS Common Stock
Subject to the rights of the holders of any Preferred Stock
which may be outstanding, each holder of CVS Common Stock on the applicable
record date is entitled to receive such dividends as may be declared by the
Board of Directors of CVS (the "CVS Board") out of funds legally available
therefor, and, in the event of liquidation, to share pro rata in any
distribution of the Registrant's assets after payment or providing for the
payment of liabilities and the liquidation preference of any outstanding
Preferred Stock. Each holder of CVS Common Stock is entitled to one vote for
each share of CVS Common Stock held of record on the applicable record date on
all matters submitted to a vote of stockholders, including the election of
directors. In addition, holders of CVS ESOP Preference Stock are entitled to
vote on all matters submitted to a vote of holders of CVS Common Stock, voting
together with the CVS Common Stock as a single class. Each share of CVS ESOP
Preference Stock is entitled to the number of votes equal to the number of
shares of CVS Common Stock into which such share of CVS ESOP Preference Stock
could be converted on the record date for the applicable meeting, which is
approximately 1.16 (after giving effect to the distribution by Melville to its
shareholders on October 12, 1996 of all shares of Footstar, Inc. held by
Melville). Holders of CVS Common Stock have no cumulative voting rights or
preemptive rights to purchase or subscribe for any stock or other securities
and there are no conversion rights or redemption or sinking fund provisions
with respect to CVS Common Stock. Assuming that the Proposal is approved by
the requisite vote of Melville shareholders and that no dissenting stockholder
appraisal rights are exercised in connection with the Merger, based on the
number of shares of Melville Common Stock and Melville ESOP Preference Stock
outstanding on August 30, 1996 and the conversion of each share of Melville
capital stock into one corresponding share of CVS capital stock in the Merger,
it is anticipated that there will be approximately 106 million shares of CVS
Common Stock and approximately 5.8 million shares of CVS ESOP Preference Stock
issued and outstanding immediately after the Effective Time.
The shares of CVS Common Stock issued in the Merger will be duly
authorized, validly issued, fully paid and nonassessable.
Certain Statutory and Charter Provisions
Certain provisions of the CVS Charter and CVS Bylaws
summarized in the following paragraphs may be deemed to have an anti-
takeover effect and may delay, defer or prevent a tender offer or takeover
attempt that a stockholder might consider in its best interest, including
those attempts that might result in a premium over the market price for the
shares held by stockholders. The following is a summary of certain of
these provisions. The CVS Charter and CVS Bylaws are attached as
Appendices to the Proxy Statement, and the following summary is qualified
in its entirety by reference to such documents.
Stockholder Action by Written Consent; Special Meetings
The CVS Charter provides that any action required or permitted
to be taken at an annual or special meeting of stockholders may be
taken without a meeting upon the written consent of all
stockholders entitled to vote thereon. The CVS Charter also
provides that special meetings of the Registrant's stockholders
may only be called by the CVS Board, the Chairman of the CVS Board
or the President and may not be called by any other person
(subject to the rights of a class or series of Preferred Stock to
call special meetings of such class or series). These provisions
may make it more difficult for stockholders to take action opposed
by the Board.
Preferred Stock
Under the CVS Charter, the CVS Board will have the authority,
without further stockholder approval but subject to certain
limitations set forth in the CVS Charter, to create one or more
series of Preferred Stock, to issue shares of Preferred Stock in
such series up to the maximum number of shares of the relevant
class of Preferred Stock authorized, and to determine the
preferences, rights, privileges and restrictions of any series,
including the dividend rights, voting rights, rights and terms of
redemption, liquidating preferences, the number of shares
constituting any such series and the designation of such series.
Pursuant to this authority, the CVS Board could create and issue a
series of preferred stock with rights, privileges or restrictions,
and adopt a stockholder rights plan, having the effect of
discriminating against an existing or prospective holder of such
securities as a result of such security holder beneficially owning
or commencing a tender offer for a substantial amount of CVS
Common Stock. One of the effects of authorized but unissued and
unreserved shares of capital stock may be to render more difficult
or discourage an attempt by a potential acquiror to obtain control
of CVS by means of a merger, tender offer, proxy contest or
otherwise, and thereby protect the continuity of the Registrant's
management. The issuance of such shares of capital stock may have
the effect of delaying, deferring or preventing a change in
control of CVS without any further action by the stockholders of
CVS.
Certain Provisions Relating to Business Combinations
Article Fifth of the CVS Charter ("Article Fifth") provides
that any "Business Combination" with a "Related Person" requires,
in addition to any vote required by law, the affirmative approval
of at least 66 2/3% of the outstanding shares of Voting Stock (as
defined in Article Fifth), voting together as a single class, held
by stockholders other than a Related Person, unless, among other
things, (i) the Continuing Directors (as defined in Article
Fifth), by at least 66 2/3% vote of such Continuing Directors,
have expressly approved such Business Combination either in
advance of or subsequent to such Related Person's having become a
Related Person or (ii) certain fair price criteria and disclosure
obligations are satisfied. The term "Related Person" is defined to
mean (a) any Person (other than CVS or any wholly owned
subsidiary) that, alone or together with any Affiliates and
Associates, is or becomes the Beneficial Owner of an aggregate of
10% or more of the outstanding Voting Stock, and (b) any Affiliate
or Associate of any such Person, provided, however, that the term
"Related Person" shall not include (x) a Person whose acquisition
of such aggregate percentage of Voting Stock was approved in
advance by at least 66 2/3% of the Continuing Directors or (y) any
pension, profit sharing, employee stock ownership or other
employee benefit plan of CVS or any subsidiary, all of the capital
stock of or equity interest in which subsidiary is owned by CVS
and one or more subsidiaries or CVS, or any trustee or fiduciary
when acting in such capacity with respect to any such plan. The
term "Business Combination" is defined to mean (a) any merger or
consolidation of CVS or a subsidiary with or into a Related
Person, (b) any sale, lease, exchange, transfer or other
disposition, including without limitation by way of a mortgage or
any other security device, of any Substantial Amount (as defined
in Article Fifth) of the assets of CVS, one or more subsidiaries
or CVS and one or more subsidiaries to a Related Person, (c) the
adoption of any plan or proposal for the liquidation or
dissolution of CVS proposed by or on behalf of any Related Person,
(d) any sale, lease, exchange, transfer or other disposition,
including without limitation by way of a mortgage or any other
security device, of any substantial amount of the assets of a
Related Person to CVS, one or more subsidiaries, or CVS and one or
more subsidiaries, (e) the issuance of any securities of CVS, one
or more subsidiaries or CVS and one or more subsidiaries to a
Related Person or to a Person that giving effect thereto, would be
a Related Person other than the issuance on a pro rata basis to
all holders of stock of the same class pursuant to a stock split
or stock dividend, (f) any reclassification of securities,
recapitalization of CVS, or any merger or consolidation of CVS
with or into one or more subsidiaries or any other transaction
that would have the effect, directly or indirectly, of increasing
the voting power or other equity interest of a Related Person in
CVS, (g) any loan, advance, guaranty, pledge or other financial
assistance by CVS, one or more subsidiaries or CVS and one or more
subsidiaries to or for the benefit, directly or indirectly (except
proportionately as a stockholder), of a Related Person, (h) any
agreement, contract or other arrangement providing for any Business
Combination and (i) any series of transactions that a majority of
Continuing Directors determines are related and that, taken
together, would constitute a Business Combination.
Delaware Takeover Statute
The Registrant is subject to Section 203 of the Delaware GCL
("Section 203"). In general, Section 203 prohibits a publicly held
Delaware corporation from engaging in a "business combination" with
an "interested stockholder" for a period of three years following
the date that such stockholder became an interested stockholder,
unless (i) prior to such date either the business combination or
the transaction which resulted in the stockholder becoming an
interested stockholder is approved by the board of directors of
the corporation, (ii) upon consummation of the transaction which
resulted in the stockholder becoming an interested stockholder,
the interested stockholder owns at least 85% of the voting stock
of the corporation outstanding at the time the transaction
commenced (excluding for purposes of determining the number of
shares outstanding, shares owned by (A) persons who are both
directors and officers and (B) employee stock plans in certain
circumstances), or (iii) on or after such date the business
combination is approved by the board and authorized at an annual
or special meeting of stockholders, and not by written consent, by
the affirmative vote of at least 66 2/3% of the outstanding voting
stock which is not owned by the interested stockholder. A
"business combination" includes a merger, consolidation, asset
sale, or other transaction resulting in a financial benefit to the
interested stockholder. An "interested stockholder" is a person
who, together with affiliates and associates, owns (or within
three years, did own) 15% or more of the corporation's voting
stock. The restrictions imposed by Section 203 will not apply to a
corporation if, among other things, (i) the corporation's original
certificate of incorporation contains a provision expressly
electing not to be governed by Section 203 or (ii) 12 months have
passed after the corporation, by action of its stockholders
holding a majority of the outstanding stock, adopts an amendment
to its certificate of incorporation or bylaws expressly electing
not to be governed by Section 203. CVS has not elected out of
Section 203 and, therefore, the restrictions imposed by Section
203 will apply to CVS.
Item 5. Financial Statements and Exhibits.
(a) Financial Statements
No financial statements are being filed with this Registration
Statement because the consolidated capital structure and balance
sheet of the Registrant immediately after the consummation of the
Merger will be substantially the same as the capital structure and
balance sheet of Melville, the predecessor, immediately prior
thereto.
(b) Exhibits.
Exhibit No. Description
- ---------------- ------------------------------------------------------------
2.1 The Melville Corporation Proxy Statement dated October
7, 1996 for the Special Meeting of Shareholders scheduled
for November 19, 1996 (the "Proxy Statement"), which is
incorporated herein by reference to Melville's definitive
Proxy Statement on Schedule 14A dated October 7, 1996.
2.2 Agreement and Plan of Merger dated as of August 30,
1996 by and among Melville, Merger Subsidiary and CVS
is attached as Appendix A to the Proxy Statement.
3.1 Restated Certificate of Incorporation of Melville, as
amended as of April 18, 1990 (incorporated by reference
to Exhibit 3 filed with Melville's Quarterly Report on
Form 10-Q for the fiscal quarter ended June 30, 1990).
3.2 Form of Amended and Restated Certificate of
Incorporation of the Registrant (the "CVS Charter") to be
filed with the Secretary of State of the State of Delaware
prior to the Effective Time (incorporated by reference to
Appendix B to the Proxy Statement).
3.3 By-Laws of Melville, as amended through March 8, 1995
(incorporated by reference to Exhibit 3(b) filed with
Melville's Annual Report on Form 10-K for the fiscal
year ended December 31, 1994). A further amendment to
the Melville bylaws was adopted on October 9, 1996 and
is filed herewith.
3.4 Form of Bylaws of the Registrant (the "CVS Bylaws") to
be adopted by the Board of Directors of the Registrant
prior to the Effective Time (incorporated by reference to
Appendix C to the Proxy Statement).
4 Pursuant to Regulation S-K, Item 601(b)(4)(iii)(A), no
instrument which defines the rights of holders of long-
term debt of the Registrant and its subsidiaries is
filed herewith. The Registrant hereby agrees to furnish
a copy of any such instrument to the Securities and
Exchange Commission upon request.
4.1 Specimen Common Stock Certificate.
4.2 Form of Amended and Restated Certificate of
Incorporation of the Registrant (see Exhibit 3.2 hereto).
4.3 Form of Bylaws of the Registrant (see Exhibit 3.4 hereto).
10(i)(1) Stock Purchase Agreement dated as of October 14, 1995
between The TJX Companies, Inc. and Melville, as
amended November 17, 1995 (incorporated by reference
to Exhibits 2.1 and 2.2 to Melville's Current Report on
Form 8-K dated December 4, 1995).
10(i)(2) Stock Purchase Agreement dated as of March 25, 1996
between Melville and Consolidated Stores Corporation, as
amended May 3, 1996 (incorporated by reference to
Exhibits 2.1 and 2.2 to Melville's Current Report on
Form 8-K dated May 5, 1996).
10(i)(3) Distribution Agreement dated as of September 24, 1996
among Melville, Footstar, Inc. and Footstar Center, Inc.
(incorporated by reference to Exhibit 99.1 to Melville's
Current Report on Form 8-K dated October 28, 1996).
10(i)(4) Tax Disaffiliation Agreement dated as of September 24,
1996 among Melville, Footstar, Inc. and certain
subsidiaries named therein (incorporated by reference to
Exhibit 99.2 to Melville's Current Report on Form 8-K
dated October 28, 1996).
10(iii)(A)(i) 1973 Stock Option Plan (incorporated by reference to
Exhibit (10) (iii)(A)(i) to Melville's Annual Report on
Form 10-K for the fiscal year ended December 31, 1987).
(ii) 1987 Stock Option Plan (incorporated by reference to
Exhibit (10)(iii)(A)(iii) to Melville's Annual Report on
Form 10-K for the fiscal year ended December 31, 1987).
(iii) 1989 Directors Stock Option Plan (incorporated by
reference to Exhibit B to Melville's Annual Report on
Form 10-K for the fiscal year ended December 31, 1988).
(iv) Melville Corporation Omnibus Stock Incentive Plan.
(incorporated by reference to Exhibit B to Melville's
Annual Report on Form 10-K for the fiscal year ended
December 31, 1989 and Exhibit A to Melville's definitive
Proxy Statement dated March 7, 1995).
(v) Profit Incentive Plan of Melville Corporation
(incorporated by reference to Exhibit A to Melville's
definitive Proxy Statement dated March 14, 1994).
(vi) Supplemental Retirement Plan for Select Senior
Management of Melville Corporation I as amended
through July 1995 (incorporated by reference to Exhibit
10(iii)(A)(vii) to Melville's Annual Report on Form 10-K
for the fiscal year ended December 31, 1995).
(vii) Supplemental Retirement Plan for Select Senior
Management of Melville Corporation II as amended
through July 1995 (incorporated by reference to Exhibit
10(iii)(A)(viii) to Melville's Annual Report on Form 10-K
for the fiscal year ended December 31, 1995).
(viii) Income Continuation Policy for Select Senior Executives
of Melville Corporation as amended through May 12,
1988 (incorporated by reference to Exhibit 10 (viii) to
Melville's Annual Report on Form 10-K for the fiscal
year ended December 31, 1994).
(ix) Melville Corporation 1996 Directors Stock Plan
(incorporated by reference to Exhibit A to Melville's
definitive Proxy Statement dated March 7, 1996).
(x) Employment Agreement between Jerald S. Politzer and
the Registrant (incorporated by reference to Exhibit 10
(iii)(A)(xii) to Melville's Annual Report on Form 10-K
for the fiscal year ended December 31, 1995).
11 Statement re: Computation of Net Earnings Per Share
(incorporated by reference to Exhibit 11 to Melville's
Quarterly Report on Form 10-Q for the fiscal quarter
ended June 29, 1996 and Exhibit 11 to Melville's Annual
Report on Form 10-K for the fiscal year ended December
31, 1995, respectively).
21 Subsidiaries of the Registrant
27.1 Financial Data Schedule (incorporated by reference to
Exhibit 27 to Melville's Quarterly Report on Form 10-Q
for the quarterly period ended June 29, 1996).
27.2 Restated Financial Data Schedule - March 30, 1996
(incorporated by reference to Exhibit 27.1 to Melville's
Quarterly Report on Form 10-Q for the fiscal quarter
ended June 29, 1996).
27.3 Restated Financial Data Schedule - December 31, 1995
(incorporated by reference to Exhibit 27.2 to Melville's
Quarterly Report on Form 10-Q for the fiscal quarter
ended June 29, 1996).
27.4 Restated Financial Data Schedule - September 30, 1995
(incorporated by reference to Exhibit 27.3 to Melville's
Quarterly Report on Form 10-Q for the quarterly period
ended June 29, 1996).
27.5 Restated Financial Data Schedule - July 1, 1995
(incorporated by reference to Exhibit 27.4 to Melville's
Quarterly Report on Form 10-Q for the quarterly period
ended June 29, 1996).
27.6 Restated Financial Data Schedule - April 1, 1995
(incorporated by reference to Exhibit 27.5 to Melville's
Quarterly Report on Form 10-Q for the quarterly period
ended June 29, 1996).
27.7 Restated Financial Data Schedule - December 31, 1994
(incorporated by reference to Exhibit 27.6 to Melville's
Quarterly Report on Form 10-Q for the quarterly period
ended June 29, 1996).
27.8 Restated Financial Data Schedule - October 1, 1994
(incorporated by reference to Exhibit 27.7 to Melville's
Quarterly Report on Form 10-Q for the quarterly period
ended June 29, 1996).
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this
registration statement to be signed on its behalf by the undersigned, thereto
duly authorized.
CVS CORPORATION
By: /s/ Stanley P. Goldstein
------------------------------
Name: Stanley P. Goldstein
Title: Chairman of the Board
and Chief Executive Officer
Dated: November 4, 1996
Exhibit 3.3
Melville Corporation
Meeting of the Board of Directors
October 9, 1996
Amendments to Bylaws
RESOLVED, that Article II, Section 1 of the Corporation's by-laws
is hereby amended to read in its entirety as follows:
"Section 1. NUMBER OF DIRECTORS. The number of directors
of the Corporation shall be thirteen."
RESOLVED, that the first paragraph of Article IV, Section 1 of the
Corporation's by-laws is hereby amended to read in its entirety as follows:
"Section 1. TITLES AND TERMS OF OFFICE. The executive
officers of the corporation shall be the Chairman of the Board of
Directors and a Vice Chairman, each of whom shall be a member of
the Board of Directors, and may include a President, such number
of Executive Vice Presidents, Senior Vice Presidents and/or Vice
Presidents, a Controller, a Treasurer and/or a Secretary, as the
Board of Directors shall determine, all of whom shall be chosen by
the Board of Directors."
RESOLVED, that Article IV, Section 3 of the Corporation's by-laws
is hereby amended to read in its entirety as follows:
"Section 3. VICE CHAIRMAN. The Vice Chairman shall have
such authority and perform such duties as the Board of Directors,
the Executive Committee, or the Chairman of the Board of Directors
may from time to time determine. In the event that at any time no
President of the Corporation is in office, all powers of the
President shall vest in the Vice Chairman and the Vice Chairman
may exercise all powers of the President set forth in these
by-laws."
RESOLVED, that Article IV, Section 4 of the Corporation's by-laws
is hereby amended to read in its entirety as follows:
"Section 4. PRESIDENT. The President, if any, shall have
such authority and shall perform such duties as the Board of
Directors, the Executive Committee, or the Chairman of the Board
of Directors may from time to time determine. He shall exercise
the powers of the Chairman of the Board of Directors during his
absence or inability to act."
RESOLVED, that Article IV, Section 7 of the Corporation's by-laws
is hereby amended to read in its entirety as follows:
"Section 7. PRINCIPAL ACCOUNTING OFFICER. A Controller or
other officer designated by the Board of Directors shall be the
principal accounting officer and subject to the direction of the
principal financial officer, he shall have supervision over all
the accounts and account books of the corporation. He shall have
such other powers and perform such other duties as from time to
time may be assigned to him by the principal financial officer,
and shall exercise the powers of the principal financial officer
during his absence or inability to act."
EXHIBIT 4.1
COMMON STOCK COMMON STOCK
NUMBER SHARES
CVS
CVS CORPORATION
Incorporated under CUSIP
the laws of Delaware SEE REVERSE FOR CERTAIN DEFINITIONS
This is to Certify that
is the owner of
FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $.01 EACH OF
THE COMMON STOCK OF CVS CORPORATION (hereinafter referred to as the
"Corporation"), transferable on the books of the Corporation by the
holder hereof in person or by duly authorized attorney upon surrender of
this certificate properly endorsed. This certificate and the shares
represented hereby are issued and shall be held subject to all of the
provisions of the Certificate of Incorporation, as amended, of the
Corporation (a copy of which certificate is on file with the Transfer
Agent), to all of which the holder by acceptance hereof assents. This
certificate is not valid until countersigned by the Transfer Agent and
registered by the Registrar.
Witness the seal of the Corporation and the signatures of its duly
authorized officers.
CERTIFICATE OF STOCK
Dated:
CVS CORPORATION
Corporate Seal 1996
Delaware
Secretary Chairman of the Board
Countersigned and Registered:
ChaseMellon Shareholder Services, L.L.C.
TRANSFER AGENT AND REGISTRAR
CVS CORPORATION
The Corporation will furnish to any shareholder upon request and
without charge a full statement of the designations, relative rights,
preferences and limitations of the shares of each class of shares
authorized to be issued, including the designation, relative rights,
preferences and limitations of each series of preferred stock so far as the
same have been fixed and the authority of the Board of Directors to
designate and fix the relative rights, preferences and limitations of other
shares.
The following abbreviations, when used in the inscription on the
face of this certificate, shall be construed as though they were written
out in full according to applicable laws or regulations:
TEN COM -- as tenants in common
TEN ENT -- as tenants by the entireties
JT TEN -- as joint tenants with right of
survivorship and not as tenants
in common
UNIF GIFT MIN ACT---............Custodian................
(Cust) (Minor)
under Uniform Gifts to Minors
Act..................................
(State)
Additional abbreviations may also be used though not in the above list.
For Value Received, ___________ hereby sell, assign and transfer unto
PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE
______________________________________________________________________________
______________________________________________________________________________
PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS OF ASSIGNEE
_________________________________________________________________Shares of the
capital stock represented by the within Certificate, and do hereby
irrevocably constitute and appoint_____
______________________________________________________________________________
Attorney to transfer the said stock on the books of the within-named
Corporation with full power of substitution in the premises.
Dated,___________________________
____________________________________
Notice: The signature to this assignment must correspond with the name as
written upon the face of the certificate in every particular,
without alteration or enlargement, or any change whatever.
Signature(s) Guaranteed:
______________________________________________________________________________
THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
(BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH
MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT
TO S.E.C. RULE 17Ad-15.
Exhibit 21
PARENTS AND SUBSIDIARIES AS OF OCTOBER 16, 1996
The following will apply assuming the transaction of succession is
consummated.
The Registrant will be the parent corporation of Melville
Corporation, a New York corporation ("Melville"). Melville is the direct
parent corporation of the following Minnesota corporations, the majority of
which also operate specialty retail chain stores: CVS H.C., Inc.; Bob's H.C.,
Inc.; and Bloomington M N., L.T., Inc.
Bloomington M N., L.T., Inc. is the parent corporation of Rockford
L.T., Inc., which is the parent corporation of 250 subsidiaries, all of which
were formed to operate specialty retail stores, all located in the United
States, selling quality brand name linens, towels, bath and other household
items.
CVS H.C., Inc. is the parent corporation of Nashua Hollis CVS,
Inc., which is the parent corporation of 1,145 subsidiaries, all of which were
formed to operate specialty retail stores located in the United States,
selling prescription drugs, health and beauty care products.
Bob's H.C., Inc. is the parent corporation of Amherst NY Bob's,
Inc., which is the parent corporation of 59 subsidiaries which were formed to
operate specialty retail stores located in the United States, selling casual
clothing and footwear for the entire family.
The Registrant is an indirect parent corporation of LNT, Inc. a
New Jersey corporation, Bob's, Inc., a Connecticut corporation, CVS of DC &
VA, Inc., a Maryland corporation, Linens 'n Things Center, Inc., a California
corporation, Bob's Stores Center, Inc., a New Hampshire corporation, CVS
Center, Inc., a New Hampshire corporation, all of which are included in the
consolidated financial statements of the Registrant.
CVS, Inc. (formerly known as CVS Distribution, Inc.) is the parent
corporation of Melville Realty Company, Inc., a New York corporation, which is
the parent corporation of Melville Realty Management Corporation, MREFC, Inc.,
Danbury MRC, Inc., MRC Manchester Devco, Inc., Amherst MRC Devco, Inc., MRC
Woodlands Devco, Inc., MRC Henderson Devco, Inc., MRC Westbury Devco, Inc.,
MRC Norwalk Devco, Inc., and MRC Staten Island Devco, Inc.
Several of the subsidiaries referred to in this Exhibit have not
yet opened their stores for business, and several no longer operate any
stores. All of the subsidiaries referred to herein are included in the
consolidated financial statements of the Registrant.
The names of other subsidiaries are omitted as, considered in the
aggregate as a single subsidiary, they would not constitute a significant
subsidiary.
